Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 14/20 | 0.39 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.36 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.36 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.35 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.34 |
| ▸ | SLC2A2 | P11168 | 1/20 | 0.34 |
| ▸ | SLC2A3 | P11169 | 1/20 | 0.34 |
| ▸ | SLC2A4 | P14672 | 1/20 | 0.34 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10136930 | 0.93 | CRHR1 (0.40) | CRHR1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL10136299 | 0.91 | SLC2A1 (0.33) | SLC2A1SLC2A2SLC2A3SLC2A4 | |
| SCHEMBL10136639 | 0.90 | SLC2A1 (0.34) | SLC2A1SLC2A2SLC2A3SLC2A4 | |
| SCHEMBL10136315 | 0.83 | MDM2 (0.32) | CRHR1 | |
| SCHEMBL12117036 | 0.83 | CRHR1 (0.39) | CRHR1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL10136623 | 0.83 | DHODH (0.35) | — | |
| SCHEMBL10075531 | 0.80 | CRHR1 (0.37) | CRHR1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL12113196 | 0.80 | MAPK14 (0.38) | CRHR1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL10075532 | 0.80 | CRHR1 (0.36) | CRHR1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL12113385 | 0.80 | CRHR1 (0.36) | CRHR1MAPK13MAPK12MAPK11MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2582688-B1 | ANTHRANILIC ACID DIAMIDE DERIVATIVES | BAYER IP GMBH (DE) | 2015-10-07 | — | — | EP | disclosed |
| US-8791139-B2 | Anthranilic diamide derivatives | BAYER CROPSCIENCE AG (DE) | 2014-07-29 | — | — | US | disclosed |
| US-20120015980-A1 | ANTHRANILIC DIAMIDE DERIVATIVES | BAYER CROPSCIENCE AG (DE) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015980-A1 | ANTHRANILIC DIAMIDE DERIVATIVES | DDT, QDPR, ANTXR2 | CRHR1 4128/4885MAPK13 3441/4885MAPK12 3047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.